FAVORABLE SAFETY PROFILE OF TIRBANIBULIN 1% OINTMENT FOR ACTINIC KERATOSIS: POOLED RESULTS FROM TWO PHASE 3 STUDIES

被引：0
|
作者：
Du Jardin, Kristian Gaarn [1 ]
Schlesinger, Todd [2 ]
Bhatia, Neal [3 ]
Berman, Brian [4 ]
Padulles, Laura [5 ]
Cutler, David [6 ]
Lebwohl, Mark [7 ]
机构：
[1] Almirall, Global Med Affairs, Barcelona, Spain
[2] Clin Res Ctr Carolinas, Charleston, SC USA
[3] Therapeut Clin Res, San Diego, CA USA
[4] Univ Miami, Miller Sch Med, Dept Dermatol & Cutaneous Surg, Miami, FL 33136 USA
[5] Almirall, Barcelona, Spain
[6] Athenex Inc, Buffalo, NY USA
[7] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
来源：
ACTA DERMATO-VENEREOLOGICA | 2022年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
PW15
引用
收藏
页码：30 / 30
页数：1
相关论文
共 50 条
  • [21] Efficacy and safety of tirbanibulin 1% ointment in actinic keratoses: Data from two phase-III trials and the real-life clinical practice presented at the European Academy of Dermatology and Venereology Congress 2022
    Pellacani, G.
    Schlesinger, T.
    Bhatia, N.
    Berman, B.
    Lebwohl, M.
    Cohen, J. L.
    Patel, G. K.
    Kunstfeld, R.
    Hadshiew, I.
    Lear, J. T.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2024, 38 : 3 - 15
  • [22] Crisaborole ointment improves global atopic dermatitis severity: Pooled results from two phase 3 clinical trials
    Fowler, J. F.
    Sidbury, B.
    Zaenglein, A. L.
    Pariser, D. M.
    Cook-Bolden, F. E.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2018, 59 : 66 - 66
  • [23] Crisaborole ointment improves global atopic dermatitis severity: Pooled results from two phase 3 clinical trials
    Fowler, J.
    Sidbury, R.
    Zaenglein, A. L.
    Pariser, D. M.
    Cook-Bolden, F. E.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2017, 137 (10) : S193 - S193
  • [24] Crisaborole ointment improves global atopic dermatitis severity: Pooled results from two phase 3 clinical trials
    Fowler, Joseph
    Sidbury, Robert
    Zaenglein, Andrea
    Pariser, David
    Cook-Bolden, Fran
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB86 - AB86
  • [25] Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies
    Sandborn, William J.
    Feagan, Brian G.
    Danese, Silvio
    O'Brien, Christopher D.
    Ott, Elyssa
    Marano, Colleen
    Baker, Thomas
    Zhou, Yiying
    Volger, Sheri
    Tikhonov, Ilia
    Gasink, Christopher
    Sands, Bruce E.
    Ghosh, Subrata
    INFLAMMATORY BOWEL DISEASES, 2021, 27 (07) : 994 - 1007
  • [26] R-850: A new immune response modifier for the treatment of actinic keratosis: Results of two phase II studies
    Williford, P
    Brown, M
    Phillips, T
    Fenyk, J
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 54 (03) : AB73 - AB73
  • [27] Pooled Safety Results from Two Phase-3 Trials of Guselkumab in Patients with Psoriatic Arthritis Through 1 Year
    Ritchlin, Christopher
    Rahman, Proton
    Helliwell, Philip
    Boehncke, Wolf-Henning
    McInnes, Iain
    Gottlieb, Alice
    Kafka, Shelly
    Kollmeier, Alexa
    Hsia, Elizabeth
    Xu, Xie
    Shawi, May
    Sheng, Shihong
    Agarwal, Prasheen
    Zhou, Bei
    Ramachandran, Paraneedharan
    Mease, Philip
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [28] Long-term safety and disease control with Ruxolitinib cream in atopic dermatitis: Pooled results from two phase 3 studies
    Papp, K.
    Szepietowski, J. C.
    Kircik, L.
    Toth, D.
    Eichenfield, L. F.
    Forman, S. B.
    Kuligowski, M. E.
    Venturanza, M. E.
    Ren, H.
    Simpson, E. L.
    EXPERIMENTAL DERMATOLOGY, 2021, 30 : 43 - 43
  • [29] POOLED SAFETY RESULTS FROM TWO PHASE-3 TRIALS OF GUSELKUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS THROUGH 1 YEAR
    Ritchlin, C. T.
    Rahman, P.
    Helliwell, P.
    Boehncke, W. H.
    Mcinnes, I.
    Gottlieb, A. B.
    Kafka, S.
    Kollmeier, A.
    Hsia, E. C.
    Xu, X. L.
    Shawi, M.
    Sheng, S.
    Agarwal, P.
    Zhou, B.
    Ramachandran, P.
    Mease, P. J.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1300 - 1301
  • [30] Efficacy and safety of methyl aminolaevulinate cream activated by daylight in actinic keratosis: two randomized, investigator-blinded, controlled, phase 3 studies in Europe and Australia
    Szeimies, R. -M.
    Basset-Seguin, N.
    Rubel, D.
    Shumack, S.
    Leclerc, S.
    Kerrouche, N.
    Lacour, J. P.
    BRITISH JOURNAL OF DERMATOLOGY, 2014, 171 (03) : E89 - E89
12345